BeOne Medicines Total Assets Growth & History (ONC)
BeOne Medicines's total assets was $8.19B for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.19B | $2.27B | +38.30% |
| 2024 | 2024-12-31 | $5.92B | $115.6M | +1.99% |
| 2023 | 2023-12-31 | $5.81B | −$574.0M | −9.00% |
| 2022 | 2022-12-31 | $6.38B | −$2.16B | −25.26% |
| 2021 | 2021-12-31 | $8.54B | $2.93B | +52.40% |
| 2020 | 2020-12-31 | $5.60B | $3.99B | +247.38% |
| 2019 | 2019-12-31 | $1.61B | −$637.4M | −28.33% |
| 2018 | 2018-12-31 | $2.25B | $1.20B | +114.98% |
| 2017 | 2017-12-31 | $1.05B | $640.7M | +157.87% |
| 2016 | 2016-12-31 | $405.8M | $289.0M | +247.55% |
| 2015 | 2015-12-31 | $116.8M | — | — |
BeOne Medicines quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.18B | $2.88B | +45.68% |
| Q1 2026 | 2026-03-31 | $8.55B | $2.71B | +46.43% |
| Q4 2025 | 2025-12-31 | $8.19B | $2.27B | +38.30% |
| Q3 2025 | 2025-09-30 | $7.63B | $1.80B | +30.90% |
| Q2 2025 | 2025-06-30 | $6.30B | $586.2M | +10.26% |
| Q1 2025 | 2025-03-31 | $5.84B | $173.8M | +3.07% |
| Q4 2024 | 2024-12-31 | $5.92B | $115.6M | +1.99% |
| Q3 2024 | 2024-09-30 | $5.83B | $306.0M | +5.54% |
| Q2 2024 | 2024-06-30 | $5.71B | −$16.6M | −0.29% |
| Q1 2024 | 2024-03-31 | $5.67B | −$289.1M | −4.85% |
| Q4 2023 | 2023-12-31 | $5.81B | −$574.0M | −9.00% |
| Q3 2023 | 2023-09-30 | $5.52B | −$1.20B | −17.86% |
| Q2 2023 | 2023-06-30 | $5.73B | −$1.65B | −22.36% |
| Q1 2023 | 2023-03-31 | $5.96B | −$2.06B | −25.74% |
| Q4 2022 | 2022-12-31 | $6.38B | −$2.16B | −25.26% |
| Q3 2022 | 2022-09-30 | $6.73B | $1.44B | +27.23% |
| Q2 2022 | 2022-06-30 | $7.38B | $1.85B | +33.56% |
| Q1 2022 | 2022-03-31 | $8.02B | $2.20B | +37.80% |
| Q4 2021 | 2021-12-31 | $8.54B | $2.93B | +52.40% |
| Q3 2021 | 2021-09-30 | $5.29B | −$280.1M | −5.03% |
| Q2 2021 | 2021-06-30 | $5.52B | $1.62B | +41.52% |
| Q1 2021 | 2021-03-31 | $5.82B | $1.75B | +43.12% |
| Q4 2020 | 2020-12-31 | $5.60B | $3.99B | +247.38% |
| Q3 2020 | 2020-09-30 | $5.57B | $3.69B | +195.92% |
| Q2 2020 | 2020-06-30 | $3.90B | $1.75B | +81.52% |
| Q1 2020 | 2020-03-31 | $4.07B | $1.89B | +87.24% |
| Q4 2019 | 2019-12-31 | $1.61B | −$637.4M | −28.33% |
| Q3 2019 | 2019-09-30 | $1.88B | −$527.6M | −21.90% |
| Q2 2019 | 2019-06-30 | $2.15B | $496.5M | +30.02% |
| Q1 2019 | 2019-03-31 | $2.17B | $463.3M | +27.11% |
| Q4 2018 | 2018-12-31 | $2.25B | $1.20B | +114.98% |
| Q3 2018 | 2018-09-30 | $2.41B | $1.36B | +129.60% |
| Q2 2018 | 2018-06-30 | $1.65B | $1.18B | +248.93% |
| Q1 2018 | 2018-03-31 | $1.71B | $1.33B | +353.62% |
| Q4 2017 | 2017-12-31 | $1.05B | $640.7M | +157.87% |
| Q3 2017 | 2017-09-30 | $1.05B | $813.6M | +345.60% |
| Q2 2017 | 2017-06-30 | $474.0M | $222.7M | +88.66% |
| Q1 2017 | 2017-03-31 | $376.7M | $111.5M | +42.04% |
| Q4 2016 | 2016-12-31 | $405.8M | $289.0M | +247.55% |
| Q3 2016 | 2016-09-30 | $235.4M | — | — |
| Q2 2016 | 2016-06-30 | $251.2M | — | — |
| Q1 2016 | 2016-03-31 | $265.2M | — | — |
| Q4 2015 | 2015-12-31 | $116.8M | — | — |
BeOne Medicines total assets trends
Over the last five fiscal years, BeOne Medicines's total assets increased from $5.60B to $8.19B, a change of $2.59B. The latest reported quarter, Q2 2026, shows $9.18B.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗